PRECISIONscientia celebrates 20 years of communicating breakthrough science
Throughout its 20 years, PRECISIONscientia has partnered with more than 100 pharmaceutical and biotech companies, supporting over 200 brands that treat various diseases.
New Search
If you are not happy with the results below please do another search
Search
50 search results for:
Dragonfly welcomes BMS-dropped IL-12 asset back into the fold
/in Business, R&DBristol Myers Squibb returned the rights for interleukin-12 (IL-12) immunotherapy program DF6002 to its original owner, Dragonfly Therapeutics, the companies announced Monday.
Roche goes toe-to-toe with AstraZeneca’s Soliris in PNH
/in Business, Clinical Trials, R&DData from the Phase III COMMODORE 2 study show Roche-subsidiary Genentech’s investigational antibody crovalimab is non-inferior to AstraZeneca’s Soliris (eculizumab), the current standard of care in paroxysmal nocturnal hemoglobinuria (PNH).
Merck and Nectin to study novel anti-PVR candidate with Keytruda
/in Business, R&DMerck and New Jersey-based Nectin Therapeutics announced a research collaboration agreement Tuesday to study the safety and efficacy of Nectin’s investigational antibody NTX1088 in locally advanced and metastatic solid tumors.
Pharma people on the move: New Year 2023 roundup
/in February 2023, Issue Archives, Marketing & AdvertisingA review of the latest executive moves in the pharma industry.
Syneos Health and Haystack Health Partner to accelerate clinical trials with AI
/in Marketing & Advertising, TherapeuticsThe combined capabilities will help improve trial lifecycles for patients, sites, and sponsors.
Lundbeck shares spike after positive mid-term profit guidance
/in Business, TherapeuticsShares in Lundbeck rose 9% on Tuesday after the Danish drug maker posted fourth-quarter sales above forecasts and projected a more rapid increase in its profit margin in the coming years than analysts had expected.
Kidney dialysis-related infection rates higher in U.S. minorities – report
/in Health, R&D, TherapeuticsPreventable bloodstream infections related to kidney failure treatment are more common in U.S. Blacks and Hispanics than in whites, according to a report from the Centers for Disease Control and Prevention (CDC) released on Monday.
Activist investor rallies Bayer shareholders as pressure on CEO mounts – sources
/in Business, TherapeuticsBayer investor Jeff Ubben has contacted fellow shareholders in the German group, investors and sources familiar with the matter told Reuters, in an apparent attempt to rally support for big changes at the drugs-to-pesticides company.
New York mayor ending COVID vaccine mandate for city workers
/in Health, TherapeuticsNew York Mayor Eric Adams said on Monday that he was lifting a controversial COVID-19 vaccine mandate for municipal workers and the city’s Department of Education employees.
